Company: KROS
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001664710-25-000089
Chunk: 218

Company: Keros Therapeutics, Inc.
Filing Date: 2025-11-05
Form: 10-Q
Item: Item 1A
Chunk 218
---
hibitFiling Date3.1Amended and Restated Certificate of Incorporation of the Registrant.8-K001-392643.1April 13, 20203.2Amended and Restated Bylaws of the Registrant.8-K001-392643.1March 6, 20253.3Certificate of Designation of Series A Junior Participating Preferred Stock filed with the Secretary of State of the State of Delaware on April 9, 2025.8-K001-392643.1April 10, 20254.1**Rights Agreement, dated as of April 9, 2025 between Registrant and Computershare Trust Company, N.A., which includes the form of Certificate of Designation as Exhibit A, the form of Right Certificate as Exhibit B.8-K001-392644.1April 10, 202510.1Employment Agreement by and between Registrant and Lorena Lerner, dated as of August 6, 2025.8-K001-3926410.1August 6, 202510.2Separation and Release Agreement by and between Registrant and Christopher Rovaldi, dated as of August 6, 2025.8-K001-3926410.2August 6, 202510.3Employment Agreement by and between Registrant and Esther Cho, dated as of August 6, 2025.8-K001-3926410.3August 6, 202510.4Stock Purchase Agreement, dated as of October 15, 2025, by and between the Registrant and certain entities affiliated with ADAR1 Capital Management.8-K001-392642.1October 15, 202510.5Stock Purchase Agreement, dated as of October 15, 2025, by and between the Registrant and certain entities affiliated with Pontifax Venture Capital.8-K001-392642.2October 15, 202531.1*Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.31.2*Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to